HBM Healthcare Investments AG

  • ISIN: CH0012627250
  • Land: Schweiz

Nachricht vom 07.05.2021 | 07:18

Changes to the Board of Directors of HBM Healthcare Investments Ltd

HBM Healthcare Investments AG / Key word(s): Annual Results

07-May-2021 / 07:18 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

Media Release

Follow us on  @HbmHealthcare

Zug, 7 May 2021

Board of Directors of HBM Healthcare Investments Ltd proposes Dr Elaine V. Jones, an experienced and well connected executive, to be elected to the Board of Directors at the Shareholders' Meeting on 18 June 2021. In this regard, the Company refers to its announcement of 2 November 2020. 

Dr Jones has more than 20 years of investment experience in venture capital financing, focusing on biosciences. For more than ten years, she was vice-president at Pfizer Ventures with responsibility for managing investments in biotechnology and healthcare companies. Prior to that, Dr Jones worked at EuclidSR Partners and at SR One, the former venture capital fund of GlaxoSmithKline.

The three long-standing members of the Board of Directors, Prof. Dr Heinz Riesenhuber (Vice Chairman), Dr Eduard E. Holdener and Robert A. Ingram, are retiring and therefore not standing for re-election at the forthcoming Shareholders' Meeting . 

'Over the last two decades, Heinz, Ed and Bob have been instrumental in establishing and building up our company. On behalf of the Board of Directors and the Mangement I thank them for their valuable services and enormous commitment  over the years and wish them all the best for their personal future. At the same time, we are looking forward to working with Elaine Jones and the other The existing directors Ruedi Lanz, Germano Giuliani and Stella Xu.' comments Chairman Hans Peter Hasler.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.

End of ad hoc announcement

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

Deutsche Wohnen SE: Freiwilliges öffentliches Übernahmeangebot von Vonovia voraussichtlich nicht erfolgreich

23. Juli 2021, 19:10

Aktueller Webcast


H1 2021 Analyst Call

04. August 2021

Aktuelle Research-Studie

Original-Research: Diversified Energy PLC (von First Berlin Equity Research GmbH): Kaufen Diversified Energy PLC

23. Juli 2021